Showing results (21-30 of 29) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Frontiers in Immunology|June 20, 2022
B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint BlockadeShubhra Singh, Jason Roszik, Neeraj Saini, et al.Journal for Immunotherapy of Cancer|November 25, 2023
Chimeric antigen receptor T cells to target CD79b in B-cell lymphomasFuliang Chu, Jingjing Cao, Jingwei Liu, et al.International Journal of Cancer|April 29, 2014
Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphomaKui Shin Voo, Myriam Foglietta, Elena Percivalle, et al.The Journal of Experimental Medicine|February 23, 2011
Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammationAlexander Pedroza-Gonzalez, Kangling Xu, Te-Chia Wu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived SpecimensKatja Karjalainen, Diana E Jaalouk, Carlos Bueso-Ramos, et al.Cancer Research|January 7, 2006
Ligand-directed surface profiling of human cancer cells with combinatorial peptide librariesMikhail G Kolonin, Laura Bover, Jessica Sun, et al.Cell Reports. Medicine|February 18, 2026
Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancerZecheng Yang, Madelaine S Theardy, Shuaitong Chen, et al.Journal for Immunotherapy of Cancer|July 4, 2024
Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinationsJane E Willoughby, Lang Dou, Sabyasachi Bhattacharya, et al.Nature Medicine|September 29, 2022
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escapeYe Li, Rafet Basar, Guohui Wang, et al.Pageof 3